{"product_id":"cagrilintide-10mg","title":"Cagrilintide 10mg vial","description":"\u003ch3\u003e\n\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003e                                \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003eFOR HUMAN \u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003e\u003cstrong\u003eCONSUMPTION\u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003cp class=\"\" data-end=\"866\" data-start=\"288\"\u003e\u003cstrong data-end=\"304\" data-start=\"288\"\u003eCagrilintide\u003c\/strong\u003e is a novel, long-acting amylin analogue under development primarily for \u003cstrong data-end=\"399\" data-start=\"377\"\u003eobesity management\u003c\/strong\u003e and \u003cstrong data-end=\"439\" data-start=\"404\"\u003etype 2 diabetes mellitus (T2DM)\u003c\/strong\u003e. It mimics and extends the physiological effects of endogenous amylin—a pancreatic hormone co-secreted with insulin—by regulating \u003cstrong data-end=\"616\" data-start=\"570\"\u003egastric emptying, satiety, and food intake\u003c\/strong\u003e. Cagrilintide is administered \u003cstrong data-end=\"662\" data-start=\"647\"\u003eonce weekly\u003c\/strong\u003e via subcutaneous injection and is being investigated both as \u003cstrong data-end=\"739\" data-start=\"724\"\u003emonotherapy\u003c\/strong\u003e and in \u003cstrong data-end=\"779\" data-start=\"747\"\u003ecombination with semaglutide\u003c\/strong\u003e, a GLP-1 receptor agonist, in a dual-agonist formulation referred to as \u003cstrong data-end=\"865\" data-start=\"852\"\u003eCagriSema\u003c\/strong\u003e.\u003c\/p\u003e\n\u003chr class=\"\" data-end=\"871\" data-start=\"868\"\u003e\n\u003ch2 class=\"\" data-end=\"902\" data-start=\"873\"\u003e\u003cstrong data-end=\"902\" data-start=\"876\"\u003e2. Mechanism of Action\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp class=\"\" data-end=\"983\" data-start=\"904\"\u003eCagrilintide exerts its pharmacologic effects through dual receptor activation:\u003c\/p\u003e\n\u003cul data-end=\"1213\" data-start=\"985\"\u003e\n\u003cli class=\"\" data-end=\"1103\" data-start=\"985\"\u003e\n\u003cp class=\"\" data-end=\"1103\" data-start=\"987\"\u003e\u003cstrong data-end=\"1015\" data-start=\"987\"\u003eAmylin Receptor Agonism:\u003c\/strong\u003e Enhances satiety, delays gastric emptying, and reduces postprandial glucagon secretion.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"1213\" data-start=\"1104\"\u003e\n\u003cp class=\"\" data-end=\"1213\" data-start=\"1106\"\u003e\u003cstrong data-end=\"1155\" data-start=\"1106\"\u003eCalcitonin Receptor Agonism (minor activity):\u003c\/strong\u003e Contributes to appetite regulation and weight modulation.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"\" data-end=\"1411\" data-start=\"1215\"\u003eThis dual activity distinguishes cagrilintide from endogenous amylin and its predecessor, \u003cstrong data-end=\"1320\" data-start=\"1305\"\u003epramlintide\u003c\/strong\u003e, by offering \u003cstrong data-end=\"1367\" data-start=\"1334\"\u003eprolonged receptor engagement\u003c\/strong\u003e and \u003cstrong data-end=\"1410\" data-start=\"1372\"\u003egreater weight-reduction potential\u003c\/strong\u003e.\u003c\/p\u003e\n\u003chr class=\"\" data-end=\"1416\" data-start=\"1413\"\u003e\n\u003ch2 class=\"\" data-end=\"1445\" data-start=\"1418\"\u003e\u003cstrong data-end=\"1445\" data-start=\"1421\"\u003e3. Clinical Efficacy\u003c\/strong\u003e\u003c\/h2\u003e\n\u003ch3 class=\"\" data-end=\"1478\" data-start=\"1447\"\u003e\u003cstrong data-end=\"1478\" data-start=\"1451\"\u003e3.1. Monotherapy Trials\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"\" data-end=\"1710\" data-start=\"1480\"\u003eIn a \u003cstrong data-end=\"1533\" data-start=\"1485\"\u003ePhase 2 randomized, placebo-controlled trial\u003c\/strong\u003e (Marre et al., \u003cem data-end=\"1561\" data-start=\"1549\"\u003eThe Lancet\u003c\/em\u003e, 2021), over 300 adults with obesity received varying doses of cagrilintide (0.3–4.5 mg) or liraglutide 3.0 mg daily for 26 weeks. Results included:\u003c\/p\u003e\n\u003cul data-end=\"1962\" data-start=\"1712\"\u003e\n\u003cli class=\"\" data-end=\"1791\" data-start=\"1712\"\u003e\n\u003cp class=\"\" data-end=\"1791\" data-start=\"1714\"\u003e\u003cstrong data-end=\"1739\" data-start=\"1714\"\u003eMean weight reduction\u003c\/strong\u003e of up to \u003cstrong data-end=\"1757\" data-start=\"1749\"\u003e8.1%\u003c\/strong\u003e at the highest cagrilintide dose.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"1860\" data-start=\"1792\"\u003e\n\u003cp class=\"\" data-end=\"1860\" data-start=\"1794\"\u003eSuperior weight loss versus liraglutide (6.8%) and placebo (1.6%).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"1962\" data-start=\"1861\"\u003e\n\u003cp class=\"\" data-end=\"1962\" data-start=\"1863\"\u003eImprovements in waist circumference, systolic blood pressure, and patient-reported appetite scores.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 class=\"\" data-end=\"2008\" data-start=\"1964\"\u003e\u003cstrong data-end=\"2008\" data-start=\"1968\"\u003e3.2. Combination Therapy (CagriSema)\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"\" data-end=\"2083\" data-start=\"2010\"\u003eCagrilintide has shown remarkable synergy when combined with semaglutide:\u003c\/p\u003e\n\u003ch4 class=\"\" data-end=\"2159\" data-start=\"2085\"\u003e\u003cstrong data-end=\"2159\" data-start=\"2090\"\u003ePhase 2 Trial (CagriSema vs. Semaglutide vs. Cagrilintide Alone):\u003c\/strong\u003e\u003c\/h4\u003e\n\u003cul data-end=\"2378\" data-start=\"2161\"\u003e\n\u003cli class=\"\" data-end=\"2222\" data-start=\"2161\"\u003e\n\u003cp class=\"\" data-end=\"2222\" data-start=\"2163\"\u003ePopulation: Adults with \u003cstrong data-end=\"2221\" data-start=\"2187\"\u003eT2DM and overweight or obesity\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"2244\" data-start=\"2223\"\u003e\n\u003cp class=\"\" data-end=\"2244\" data-start=\"2225\"\u003eDuration: 32 weeks.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"2378\" data-start=\"2245\"\u003e\n\u003cp class=\"\" data-end=\"2256\" data-start=\"2247\"\u003eFindings:\u003c\/p\u003e\n\u003cul data-end=\"2378\" data-start=\"2259\"\u003e\n\u003cli class=\"\" data-end=\"2295\" data-start=\"2259\"\u003e\n\u003cp class=\"\" data-end=\"2295\" data-start=\"2261\"\u003e\u003cstrong data-end=\"2275\" data-start=\"2261\"\u003eCagriSema:\u003c\/strong\u003e ~15.6% weight loss.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"2336\" data-start=\"2298\"\u003e\n\u003cp class=\"\" data-end=\"2336\" data-start=\"2300\"\u003e\u003cstrong data-end=\"2329\" data-start=\"2300\"\u003eSemaglutide 2.4 mg alone:\u003c\/strong\u003e ~5.1%.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"2378\" data-start=\"2339\"\u003e\n\u003cp class=\"\" data-end=\"2378\" data-start=\"2341\"\u003e\u003cstrong data-end=\"2371\" data-start=\"2341\"\u003eCagrilintide 2.4 mg alone:\u003c\/strong\u003e ~8.1%.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"\" data-end=\"2477\" data-start=\"2380\"\u003eThis indicates an additive or possibly synergistic effect when both agents are used concurrently.\u003c\/p\u003e\n\u003ch4 class=\"\" data-end=\"2534\" data-start=\"2479\"\u003e\u003cstrong data-end=\"2534\" data-start=\"2484\"\u003eREDEFINE 2 Phase 3 Trial (2024, Novo Nordisk):\u003c\/strong\u003e\u003c\/h4\u003e\n\u003cul data-end=\"2771\" data-start=\"2536\"\u003e\n\u003cli class=\"\" data-end=\"2585\" data-start=\"2536\"\u003e\n\u003cp class=\"\" data-end=\"2585\" data-start=\"2538\"\u003ePopulation: Adults with T2DM and BMI ≥27 kg\/m².\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"2607\" data-start=\"2586\"\u003e\n\u003cp class=\"\" data-end=\"2607\" data-start=\"2588\"\u003eDuration: 68 weeks.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"2771\" data-start=\"2608\"\u003e\n\u003cp class=\"\" data-end=\"2618\" data-start=\"2610\"\u003eResults:\u003c\/p\u003e\n\u003cul data-end=\"2771\" data-start=\"2621\"\u003e\n\u003cli class=\"\" data-end=\"2667\" data-start=\"2621\"\u003e\n\u003cp class=\"\" data-end=\"2667\" data-start=\"2623\"\u003e\u003cstrong data-end=\"2643\" data-start=\"2623\"\u003eCagriSema group:\u003c\/strong\u003e 15.7% mean weight loss.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"2696\" data-start=\"2670\"\u003e\n\u003cp class=\"\" data-end=\"2696\" data-start=\"2672\"\u003e\u003cstrong data-end=\"2690\" data-start=\"2672\"\u003ePlacebo group:\u003c\/strong\u003e 3.1%.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"2771\" data-start=\"2699\"\u003e\n\u003cp class=\"\" data-end=\"2771\" data-start=\"2701\"\u003eAlso noted improvements in HbA1c, fasting glucose, and lipid profiles.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr class=\"\" data-end=\"2776\" data-start=\"2773\"\u003e\n\u003ch2 class=\"\" data-end=\"2811\" data-start=\"2778\"\u003e\u003cstrong data-end=\"2811\" data-start=\"2781\"\u003e4. Safety and Tolerability\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp class=\"\" data-end=\"2886\" data-start=\"2813\"\u003eAcross studies, cagrilintide has demonstrated a favorable safety profile:\u003c\/p\u003e\n\u003cul data-end=\"3302\" data-start=\"2888\"\u003e\n\u003cli class=\"\" data-end=\"3011\" data-start=\"2888\"\u003e\n\u003cp class=\"\" data-end=\"3011\" data-start=\"2890\"\u003e\u003cstrong data-end=\"2921\" data-start=\"2890\"\u003eMost common adverse events:\u003c\/strong\u003e Gastrointestinal symptoms (nausea, vomiting, constipation), dose-dependent and transient.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"3096\" data-start=\"3012\"\u003e\n\u003cp class=\"\" data-end=\"3096\" data-start=\"3014\"\u003e\u003cstrong data-end=\"3036\" data-start=\"3014\"\u003eHypoglycemia risk:\u003c\/strong\u003e Minimal when used without insulin or insulin secretagogues.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"3209\" data-start=\"3097\"\u003e\n\u003cp class=\"\" data-end=\"3209\" data-start=\"3099\"\u003e\u003cstrong data-end=\"3118\" data-start=\"3099\"\u003eCardiac safety:\u003c\/strong\u003e No significant QT prolongation; no increase in major adverse cardiovascular events (MACE).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"3302\" data-start=\"3210\"\u003e\n\u003cp class=\"\" data-end=\"3302\" data-start=\"3212\"\u003e\u003cstrong data-end=\"3231\" data-start=\"3212\"\u003eImmunogenicity:\u003c\/strong\u003e Low incidence of anti-drug antibodies; no impact on efficacy observed.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr class=\"\" data-end=\"3307\" data-start=\"3304\"\u003e\n\u003ch2 class=\"\" data-end=\"3335\" data-start=\"3309\"\u003e\u003cstrong data-end=\"3335\" data-start=\"3312\"\u003e5. Pharmacokinetics\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cul data-end=\"3604\" data-start=\"3337\"\u003e\n\u003cli class=\"\" data-end=\"3409\" data-start=\"3337\"\u003e\n\u003cp class=\"\" data-end=\"3409\" data-start=\"3339\"\u003e\u003cstrong data-end=\"3353\" data-start=\"3339\"\u003eHalf-life:\u003c\/strong\u003e Approximately 150 hours, supporting once-weekly dosing.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"3495\" data-start=\"3410\"\u003e\n\u003cp class=\"\" data-end=\"3495\" data-start=\"3412\"\u003e\u003cstrong data-end=\"3427\" data-start=\"3412\"\u003eAbsorption:\u003c\/strong\u003e Delayed Tmax (~72 hours), with stable weekly plasma concentrations.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"3604\" data-start=\"3496\"\u003e\n\u003cp class=\"\" data-end=\"3604\" data-start=\"3498\"\u003e\u003cstrong data-end=\"3514\" data-start=\"3498\"\u003eElimination:\u003c\/strong\u003e Renal excretion is minor; no dose adjustment required for mild\/moderate renal impairment.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr class=\"\" data-end=\"3609\" data-start=\"3606\"\u003e\n\u003ch2 class=\"\" data-end=\"3660\" data-start=\"3611\"\u003e\u003cstrong data-end=\"3660\" data-start=\"3614\"\u003e6. Clinical Development and Future Outlook\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp class=\"\" data-end=\"3786\" data-start=\"3662\"\u003eCagrilintide is part of Novo Nordisk’s \u003cstrong data-end=\"3736\" data-start=\"3701\"\u003eREDEFINE clinical trial program\u003c\/strong\u003e, targeting both monotherapy and dual-therapy use:\u003c\/p\u003e\n\u003cul data-end=\"4152\" data-start=\"3788\"\u003e\n\u003cli class=\"\" data-end=\"3897\" data-start=\"3788\"\u003e\n\u003cp class=\"\" data-end=\"3897\" data-start=\"3790\"\u003e\u003cstrong data-end=\"3814\" data-start=\"3790\"\u003eREDEFINE 1–6 Trials:\u003c\/strong\u003e Ongoing Phase 3 studies in various patient subgroups (obesity, T2DM, prediabetes).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"4027\" data-start=\"3898\"\u003e\n\u003cp class=\"\" data-end=\"4027\" data-start=\"3900\"\u003e\u003cstrong data-end=\"3922\" data-start=\"3900\"\u003eCombination Focus:\u003c\/strong\u003e CagriSema is expected to be a \u003cstrong data-end=\"3984\" data-start=\"3953\"\u003efirst-in-class dual peptide\u003c\/strong\u003e for chronic weight and glucose management.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"4152\" data-start=\"4028\"\u003e\n\u003cp class=\"\" data-end=\"4152\" data-start=\"4030\"\u003e\u003cstrong data-end=\"4056\" data-start=\"4030\"\u003ePotential indications:\u003c\/strong\u003e Obesity, T2DM, metabolic syndrome, possibly for cardiovascular risk reduction pending outcomes.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"\" data-end=\"4299\" data-start=\"4154\"\u003eIf regulatory approval is granted, \u003cstrong data-end=\"4241\" data-start=\"4189\"\u003eCagriSema could redefine obesity pharmacotherapy\u003c\/strong\u003e, offering superior efficacy with manageable tolerability.\u003c\/p\u003e\n\u003chr class=\"\" data-end=\"4304\" data-start=\"4301\"\u003e\n\u003ch2 class=\"\" data-end=\"4326\" data-start=\"4306\"\u003e\u003cstrong data-end=\"4326\" data-start=\"4309\"\u003e7. Conclusion\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp class=\"\" data-end=\"4702\" data-start=\"4328\"\u003eCagrilintide represents a significant advancement in metabolic therapeutics. Its ability to induce meaningful weight loss, especially in combination with GLP-1 agonists like semaglutide, places it at the forefront of next-generation obesity and diabetes management. Pending long-term safety and cardiovascular outcome data, it holds promise for widespread clinical adoption.\u003c\/p\u003e\n\u003chr class=\"\" data-end=\"4707\" data-start=\"4704\"\u003e\n\u003ch2 class=\"\" data-end=\"4730\" data-start=\"4709\"\u003e\u003cstrong data-end=\"4730\" data-start=\"4712\"\u003eKey References\u003c\/strong\u003e\u003c\/h2\u003e\n\u003col data-end=\"5111\" data-start=\"4732\"\u003e\n\u003cli class=\"\" data-end=\"4807\" data-start=\"4732\"\u003e\n\u003cp class=\"\" data-end=\"4807\" data-start=\"4735\"\u003eMarre M, et al. \u003cem data-end=\"4763\" data-start=\"4751\"\u003eThe Lancet\u003c\/em\u003e, 2021. DOI: 10.1016\/S2213-8587(21)00203-0\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"4881\" data-start=\"4808\"\u003e\n\u003cp class=\"\" data-end=\"4881\" data-start=\"4811\"\u003eDavies M, et al. \u003cem data-end=\"4857\" data-start=\"4828\"\u003eLancet Diabetes Endocrinol.\u003c\/em\u003e, 2023. PMID: 37364590\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"4960\" data-start=\"4882\"\u003e\n\u003cp class=\"\" data-end=\"4960\" data-start=\"4885\"\u003eRosenstock J, et al. \u003cem data-end=\"4928\" data-start=\"4906\"\u003eDiabetes Obes Metab.\u003c\/em\u003e, 2023. DOI: 10.1111\/dom.15951\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"5024\" data-start=\"4961\"\u003e\n\u003cp class=\"\" data-end=\"5024\" data-start=\"4964\"\u003eNovo Nordisk press release: REDEFINE 2 Trial Results, 2024\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"5111\" data-start=\"5025\"\u003e\n\u003cp class=\"\" data-end=\"5111\" data-start=\"5028\"\u003eWadden TA, et al. \u003cem data-end=\"5055\" data-start=\"5046\"\u003eObesity\u003c\/em\u003e, 2024. Clinical implications of CagriSema dual therapy.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":52684860260690,"sku":null,"price":80.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/cagrilintide_10mg.png?v=1770834903","url":"https:\/\/sciencepeptideslab.com\/products\/cagrilintide-10mg","provider":"Science Peptides Lab","version":"1.0","type":"link"}